Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
CONCLUSIONS: Prior or synchronous second malignancies are common at diagnosis of NSCLC. The sites reflect the high proportion of smokers in the population. The earlier stage of NSCLC with a second malignancy might be attributed to chance finding of NSCLC during follow-up. The second malignancy does not affect OS of NSCLC. Therefore, the exclusion of patients with second malignancies from NSCLC trials should be reconsidered.
PMID: 30062488 [PubMed - indexed for MEDLINE]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Faehling M, Schwenk B, Kramberg S, Fallscheer S, Leschke M, Sträter J, Eckert R Tags: J Cancer Res Clin Oncol Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Gastroenterology | Head and Neck Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Prostate Cancer | Smokers